off-label use of glp-1 agonists for obesity in 2016 Harnessing Receptor Treatment: Prospects and Obstacles on the Horizon Use of diabetes and anti-obesity

Building on that success, offering access to compounded GLP-1s gives medical providers and customers consistent and affordable access to effective, trusted and safe medications

doi:10.1111/dom.15948

The SURMOUNT-2 trial in patients with both obesity and type 2 diabetes showed somewhat lower but still impressive results: 12.8% to 14.7% weight loss over 72 weeks

If you would like to learn about additional peptide options, contact our team

Our process of small-batch synthesis is deliberate and meticulous, ensuring that every single vial contains the exact amino-acid sequence required, with purity levels that set the industry benchmark

FIGURE 1 Based on these findings and to investigate the early mechanisms by which the compound begins to inhibit cell growth, all cell lines were incubated with 8.4 M HC, and cell growth was monitored at various intervals over a 24-h period (i.e., 4, 8, and 24 h)